In 2018, Petrov et al. developed one of the first bicistronic AML CAR-T cell therapies targeting CD123 and CD33, showing cytotoxicity against CD123 + CD33- and CD123-CD33 + cell lines and increased survival in four leukemia mouse models [145] (Table 3). This evidence concerns the gene CD33 and acute myeloid leukemia.